Wally R Smith

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4369678/publications.pdf

Version: 2024-02-01

66	5,360	159585	128289
papers	citations	30 h-index	60 g-index

66	66	66	4101
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study. Pain, 2022, 163, 1102-1113.	4.2	9
2	A randomised controlled providerâ€blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence. British Journal of Haematology, 2022, 196, 193-203.	2.5	6
3	Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review. Journal of Pain Research, 2022, Volume 15, 879-894.	2.0	7
4	Gender-specific correlates of nonmedical use of prescription medications in a diverse primary care sample. Drug and Alcohol Dependence, 2022, 234, 109399.	3.2	1
5	How Would You Treat This Patient With Acute and Chronic Pain From Sickle Cell Disease?. Annals of Internal Medicine, 2022, 175, 566-573.	3.9	0
6	Development and validation of the sickle cell stress scaleâ€adult. European Journal of Haematology, 2022, 109, 215-225.	2.2	2
7	Indirect Economic Burden of Sickle Cell Disease. Value in Health, 2021, 24, 1095-1101.	0.3	18
8	Telehealth acceptability and opioid prescribing patterns of providers of painful chronic diseases during the COVID-19 pandemic: A survey of sickle cell providers. Journal of Opioid Management, 2021, 17, 489-497.	0.5	1
9	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813.	5.2	57
10	Development of a Severity Classification System for Sickle Cell Disease . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 625-633.	1.9	12
11	Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients. Pediatric Nephrology, 2020, 35, 883-889.	1.7	9
12	Health-related quality of life in sickle cell disease. Nature Reviews Disease Primers, 2019, 5, 27.	30.5	3
13	Development of a Framework to Describe Functions and Practice of Community Health Workers. Journal of Continuing Education in the Health Professions, 2019, 39, 265-269.	1.3	9
14	AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain. Journal of Pain, 2019, 20, 746-759.	1.4	37
15	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal of Hematology, 2019, 94, 446-454.	4.1	56
16	Lessons Learned from Building a Pediatric-to-Adult Sickle Cell Transition Program. Southern Medical Journal, 2019, 112, 190-197.	0.7	22
17	Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND). Blood, 2019, 134, 998-998.	1.4	5
18	Development and Validation of a Functional Status-Based Pain Assessment Tool. Blood, 2019, 134, 416-416.	1.4	0

#	Article	IF	Citations
19	Responsivity of Utilization Rates to the Intensity of Case Management over Time Among High-Utilizing Adults with Sickle Cell Disease. Blood, 2019, 134, 5803-5803.	1.4	0
20	Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease. Blood, 2019, 134, 2104-2104.	1.4	0
21	Using Lean Six Sigma to Develop a Patient Centered Medical Home for Adults with Sickle Cell Disease. Blood, 2019, 134, 3408-3408.	1.4	2
22	Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel. Blood, 2019, 134, 415-415.	1.4	3
23	The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study. Blood, 2019, 134, 2168-2168.	1.4	1
24	Tiered Oral Therapy Protocol for Sickle Cell Vaso-Occlusive Crisis. Blood, 2019, 134, 3446-3446.	1.4	0
25	The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study. Blood, 2019, 134, 2309-2309.	1.4	1
26	Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse. Journal of Opioid Management, 2019, 15, 323-331.	0.5	1
27	Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project. Pain Medicine, 2018, 19, 1972-1981.	1.9	4
28	Sickle cell disease. Nature Reviews Disease Primers, 2018, 4, 18010.	30.5	764
29	A Phase 3 Trial of<scp>l</scp>-Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235.	27.0	378
30	AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain. Journal of Pain, 2017, 18, 490-498.	1.4	142
31	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 429-439.	27.0	599
32	Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project. BioMed Research International, 2017, 2017, 1-10.	1.9	38
33	Survey of Physician Perspective towards Management of Pain for Chronic Conditions in the Emergency Department. Modern Clinical Medicine Research, 2017, 1, 55-70.	0.3	3
34	Self-efficacy and readiness for transition from pediatric to adult care in sickle cell disease. International Journal of Adolescent Medicine and Health, 2016, 28, 381-388.	1.3	33
35	Health literacy and disease-specific knowledge of caregivers for children with sickle cell disease. Pediatric Hematology and Oncology, 2016, 33, 121-133.	0.8	16
36	Physicians' Perception of Sickle-cell Disease Pain. Journal of the National Medical Association, 2016, 108, 113-118.	0.8	4

#	Article	IF	Citations
37	Community Health Workers as Support for Sickle Cell Care. American Journal of Preventive Medicine, 2016, 51, S87-S98.	3.0	57
38	Quality of care in sickle cell disease. Medicine (United States), 2016, 95, e4528.	1.0	41
39	Top 10 Things You Need to Know to Run Community Health Worker Programs: Lessons Learned in the Field. Southern Medical Journal, 2016, 109, 579-582.	0.7	5
40	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 2015, 125, 2656-2664.	1.4	178
41	Daily home opioid use in adults with sickle cell disease: The PiSCES project. Journal of Opioid Management, 2015, 11, 243-253.	0.5	49
42	Fatigue in Adolescents and Young Adults With Sickle Cell Disease. Journal of Pediatric Oncology Nursing, 2014, 31, 6-17.	1.5	69
43	Use of the Word â€œCrisisâ€•in Sickle Cell Disease: The Language of Sickle Cell. Journal of the National Medical Association, 2014, 106, 23-30.	0.8	2
44	Disparities in Breast and Cervical Cancer Screening in Women with Mental Illness. American Journal of Preventive Medicine, 2013, 44, 392-398.	3.0	91
45	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
46	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood, 2013, 122, 776-776.	1.4	7
47	Disease-Specific Knowledge Assessment of Caregivers Is a Better Predictor of Health Care Utilization Than Caregiver Functional Health Literacy Among Children with Sickle Cell Disease. Blood, 2012, 120, 4240-4240.	1.4	1
48	Somatic Symptom Burden in Adults with Sickle Cell Disease Predicts Pain, Depression, Anxiety, Health Care Utilization, and Quality of Life: The PiSCES Project. Psychosomatics, 2011, 52, 272-279.	2.5	70
49	Emerging Biobehavioral Factors of Fatigue in Sickle Cell Disease. Journal of Nursing Scholarship, 2011, 43, 22-29.	2.4	36
50	Frequently asked questions by hospitalists managing pain in adults with sickle cell disease. Journal of Hospital Medicine, 2011, 6, 297-303.	1.4	29
51	Sickle-Cell Pain: Advances in Epidemiology and Etiology. Hematology American Society of Hematology Education Program, 2010, 2010, 409-415.	2.5	77
52	The risks and benefits of longâ€term use of hydroxyurea in sickle cell anemia: A 17.5 year followâ€up. American Journal of Hematology, 2010, 85, 403-408.	4.1	385
53	Readiness for Transition From Pediatric Sickle Cell Care: Exploratory Analyses of Domains of Readiness and Total Scores. Blood, 2010, 116, 2576-2576.	1.4	1
54	Pain site frequency and location in sickle cell disease: The PiSCES project. Pain, 2009, 145, 246-251.	4.2	86

#	Article	IF	Citations
55	Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain, 2009, 146, 91-98.	4.2	43
56	Daily Assessment of Pain in Adults with Sickle Cell Disease. Annals of Internal Medicine, 2008, 148, 94.	3.9	478
57	Depression and Anxiety in Adults With Sickle Cell Disease: The PiSCES Project. Psychosomatic Medicine, 2008, 70, 192-196.	2.0	175
58	The role of catastrophizing in sickle cell disease â€“ The PiSCES project. Pain, 2007, 133, 39-46.	4.2	48
59	Alcohol Abuse in Sickle Cell Disease: The Pisces Project. American Journal on Addictions, 2007, 16, 383-388.	1.4	28
60	Health related quality of life in sickle cell patients: the PiSCES project. Health and Quality of Life Outcomes, 2005, 3, 50.	2.4	207
61	Understanding pain and improving management of sickle cell disease: the PiSCES study. Journal of the National Medical Association, 2005, 97, 183-93.	0.8	72
62	Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.. Blood, 2004, 104, 103-103.	1.4	3
63	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	7.4	741
64	Prognostic Judgments and Triage Decisions for Patients With Acute Congestive Heart Failure. Chest, 2002, 121, 1610-1617.	0.8	67
65	Results of Report Cards for Patients with Congestive Heart Failure Depend on the Method Used To Adjust for Severity. Annals of Internal Medicine, 2000, 133, 10.	3.9	35
66	Psychosocial determinants of health care utilization in sickle cell disease patients. Annals of Behavioral Medicine, 1997, 19, 171-178.	2.9	34